5VM
VRDN icon

5AM Venture Management’s Viridian Therapeutics VRDN Stock Holding History

5AM Venture Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-736,595
Closed -$22.9M – 22
2025
Q4 		$22.9M Hold
736,595
– – 7.21% 4
2025
Q3 		$15.9M Hold
736,595
– – 5.82% 6
2025
Q2 		$10.3M Hold
736,595
– – 3.96% 9
2025
Q1 		$9.93M Hold
736,595
– – 3.76% 10
2024
Q4 		$14.1M Hold
736,595
– – 3.37% 11
2024
Q3 		$16.8M Hold
736,595
– – 3.46% 12
2024
Q2 		$9.58M Hold
736,595
– – 2.14% 15
2024
Q1 		$12.9M Buy
736,595
+150,000
+26% +$2.91M 2.89% 15
2023
Q4 		$12.8M Buy
586,595
+176,595
+43% +$2.79M 3.39% 11
2023
Q3 		$6.29M Buy
410,000
+130,000
+46% +$2.48M 1.81% 17
2023
Q2 		$6.66M Hold
280,000
– – 1.66% 18
2023
Q1 		$7.12M Sell
280,000
-20,000
-7% -$641K 1.82% 14
2022
Q4 		$8.76M Sell
300,000
-184,891
-38% -$4.26M 2.35% 15
2022
Q3 		$9.95M Buy
+484,891
New +$8.72M 1.91% 13

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

5AM Venture Management's VRDN Position: Q1 2026 in Review

5AM Venture Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 736,595 shares — an estimated $22.9M sold.

5AM Venture Management first reported a position in VRDN in Q3 2022 and held it in 14 quarters. The position peaked at $22.9M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • 5AM Venture Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • 5AM Venture Management sold 736,595 Viridian Therapeutics shares in Q1 2026, an estimated $22.9M.
  • 5AM Venture Management first reported a position in Viridian Therapeutics in Q3 2022 and held it in 14 quarters.
  • 5AM Venture Management's Viridian Therapeutics position peaked at $22.9M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on 5AM Venture Management's 13F filing for Q1 2026, filed 15 May 2026.